Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Benitec Biopharma Inc.NASDAQ: BNTC
Net Change in Cash · Q3 FY2026 · quarter ended Mar 2026
Net change in cash turns negative
Q3 FY2026 net change in cash was -$4.03M, compared with $25.3M a year earlier. Trailing-twelve-month net change in cash was $81.23M.
Context
- Net change in cash increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly net change in cash holds near -$4.03M or moves back toward the trailing-twelve-month quarterly average of $20.31M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- 46.93M USD
- Year-over-year change
- -3.1%
- 4-year CAGR
- +47.3%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 46.93M | -3.1% |
| FY2024 | 2024-06-30 | 48.44M | +3154.2% |
| FY2023 | 2023-06-30 | (1.59M) | +89.9% |
| FY2022 | 2022-06-30 | (15.71M) | -257.6% |
| FY2021 | 2021-06-30 | 9.97M | — |
Net Change in Cash vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's LTM Mar 2026 net change in cash of $81.23M is the 2nd largest of the 10 companies compared; the peer median is $6.68M.
- Its year-over-year change of -9.2% is the 6th highest of 10, against a peer median of -7.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $85.84M | -7.8% | — | — | |
| LTM Mar 2026 | $81.23M | -9.2% | — | — | |
| LTM Mar 2026 | $53.39M | +167.3% | — | — | |
| LTM Mar 2026 | $35.17M | +105.3% | — | 38.0% | |
| FY2025 | $28.22M | -131.5% | -55.3% | 605.6% | |
| LTM Mar 2026 | $11.87M | -381.3% | -51.6% | 80.3% | |
| LTM Mar 2026 | $8.07M | +118.0% | — | 22.3% | |
| LTM Mar 2026 | $6.68M | +141.4% | — | — | |
| LTM Mar 2026 | $5.94M | -150.6% | +31.5% | 133.0% | |
| LTM Mar 2026 | $1.09M | -93.1% | — | 59.0% | |
| Peer median (excluding BNTC) | $6.68M | -7.8% | -51.6% | 69.7% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Net Income | (13.88M) | (18.21M) | (19.56M) | (21.75M) | (37.92M) |
| Depreciation & Amortization | 424K | 392K | 381K | 343K | 396K |
| Deferred Income Tax | 0 | 0 | (714K) | 0 | 0 |
| Stock-Based Compensation | 634K | 870K | 452K | 830K | 17.43M |
| Change in Working Capital | 8K | 1.04M | 714K | 1.17M | (2.73M) |
| Accounts Receivables | 28K | 1K | (50K) | (176K) | 197K |
| Inventory | (83K) | (1.09M) | (1.31M) | 0 | 0 |
| Accounts Payables | 55K | 1.09M | 1.36M | 0 | (2.38M) |
| Other Working Capital | 8K | 1.04M | 714K | 1.35M | (548K) |
| Other Non-Cash Items | (16K) | 10K | 717K | 1K | (764K) |
| Operating Cash Flow | (12.83M) | (15.9M) | (18.01M) | (19.4M) | (23.59M) |
| Capital Expenditures | (221K) | (13K) | (1K) | (179K) | (18K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (221K) | (13K) | (1K) | (179K) | (18K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 25.75M | 0 | 17.88M | 70.88M | 70.49M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.23M) | 0 | (1.87M) | (2.85M) | 0 |
| Financing Cash Flow | 22.52M | 0 | 16.02M | 68.03M | 70.49M |
| Effect of Forex Changes | 499K | 204K | 412K | (8K) | 49K |
| Net Change in Cash | 9.97M | (15.71M) | (1.59M) | 48.44M | 46.93M |
| Free Cash Flow | (13.05M) | (15.91M) | (18.01M) | (19.58M) | (23.61M) |
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.